Clinical Trials Logo

Sarcoma, Kaposi clinical trials

View clinical trials related to Sarcoma, Kaposi.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02229981 Withdrawn - Clinical trials for Diffuse Large B Cell Lymphoma

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

ABC-102
Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a sequential Phase I and IIa study to identify the maximum tolerated dose and to evaluate safety, tolerability, toxicity, pharmacokinetics and pharmacodynamics of the oral sphingosine kinase inhibitor ABC294640 specifically in patients with diffuse large B-cell lymphoma (DLBCL), including virus-associated (e.g., KSHV- or EBV-associated) DLBCL or Kaposi Sarcoma (KS) after failure of or intolerance to initial standard therapy.

NCT ID: NCT02137564 Withdrawn - HIV Infection Clinical Trials

Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma

Start date: July 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effects, good and bad, of gamma secretase inhibitor PF-03084014 and to see how well it works in treating patients with acquired immune deficiency virus (AIDS)-associated Kaposi sarcoma. Gamma secretase inhibitor PF-03084014 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may shrink the tumor.

NCT ID: NCT00521092 Withdrawn - Clinical trials for AIDS-related Kaposi Sarcoma

Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma

Start date: January 2009
Phase: Phase 2
Study type: Interventional

Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.